In this webinar featuring experts from Quench Medical and Lonza Small Molecules, a case study of an Excipient Enhanced Growth for gemcitabine as an inhaled lung cancer treatment, illustrates a pathway from feasibility studies through scale-up to commercialization.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center